Frontline Setting Boasts Multiple Treatment Options for Patients With ALL
Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.
Targeted Therapies Make Major Strides in mCRC Management
November 7th 2021The treatment algorithm in metastatic colorectal cancer has gone from accounting only for the sidedness of the primary tumor, performance status, volume of disease, and potential resectability to also include the genetics of the tumor, particularly for patients in need of second-line therapy.
Personalized Medicine Could Be the Key to Bridging Health Disparities in Cancer Care
November 4th 2021Expanding the definition of personalized medicine to include social determinants of health disparities is needed to ensure patients with cancer receive optimal care, said Karen Winkfield, MD, PhD, who added that lessons learned from the COVID-19 pandemic have sparked a new wave of enthusiasm to advocate for change and bridge existing gaps in oncology.
Bispecific Monoclonal Antibodies Lead Immune-Directed Therapies into the Future
Increases investigative efforts into bispecific monoclonal antibodies could lead to their availability to treat a broad range of hematologic and solid cancers. Their current use in practice is limited to non–small cell lung cancer, leukemia, and hemophilia.
Checkpoint Blockade Moves Needle in Molecularly Driven Endometrial Cancer Paradigm
The management of endometrial cancer, a molecularly driven malignancy with 4 distinct subtypes, has witnessed significant progress with recent regulatory approvals of checkpoint blockade alone and in combination, said Bhavana Pothuri, MD, MS.
COVID-19 Vaccination Remains Imperative for Patients with Cancer
As the COVID-19 pandemic persists, patients with cancer should receive the full vaccination with 1 of the 3 approved COVID-19 vaccines as soon as they are able, according to Steven Ludlow, PharmD, BCOP, BCPS.
Testing for Prognostic Markers Is a Necessity for Optimized CLL Care
November 3rd 2021The identification of prognostic markers at diagnosis in chronic lymphocytic leukemia is critical, says Deborah M. Stephens, DO, who explains that the results of testing for these markers can be used to educate patients on their prognosis, tailor therapy accordingly, and enroll eligible patients on clinical trials.
MRD Continues to Show Prognostic Potential in AML and Shape Treatment Decisions
Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.
Unlocking the Potential of Targeted Treatment Options for HCC
Targeted agents have restructured the treatment paradigm for patients with advanced hepatocellular carcinoma. The present challenge is to identify the patients most likely to benefit from frontline treatment regimens.
Immunotherapy in Gynecologic Cancers Shows Progress but Has a Long Way to Go
November 5th 2020Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.
Novel Combinations Carry CDK4/6 Inhibitors Into the Future in HR+/HER2- Breast Cancer
November 5th 2020Patients with advanced hormone receptor–positive, HER2-negative breast cancer still face acquired resistance, even with the most effective agents, namely CDK4/6 inhibitors, which have demonstrated unprecedented overall survival benefit in the metastatic setting.